Please assess the completion status of the following clinical trial:

Trial Title: Donor Simvastatin Treatment in Organ Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria for a donor:~* Heart transplant donor~* Age 18-60 years~* Previously healthy~* No cholesterol medication~* Normal ECHO with LVEF \>45%, normal right ventricle and normal coronary angiography~* PiO2/FiO2 \> 40kPA, normal chest radiograph and normal bronchoscopy in lung donors~Exclusion Criteria for the heart/lung donor:~* Severe left ventricular hypertrophy \> 14 mm~* High dose of inotropes (dopamine or dobutamine \> 20ug/kg/min or norepinephrine \>0.2 ug/kg/min) at the time of procurement~* Donor outside of the study country Finland~Inclusion criteria for a transplant recipient:~* Age between 18-70 for heart transplant recipients~* Male or female~* Listed for heart, lung, kidney, or liver transplantation~Exclusive Criteria for the recipient~* systemic sepsis~* a positive cross match

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Simvastatin 80 mg group (Type: ACTIVE_COMPARATOR): The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
- Control Rx (Type: EXPERIMENTAL): The transplant recipients who have received an organ from non-treated donors.

Based on this trial design, predict the completion outcome and termination type (if applicable).